Descartes-08 (mRNA CAR-T) is a Cartesian Therapeutics, Inc. program in myasthenia gravis. Its next catalyst is a Readout in Q1 2027.
All upcoming FDA decision dates on the 2026 PDUFA calendar
Indications under review: Myasthenia gravis; Myositis; Pediatric autoimmune diseases incl. juvenile dermatomyositis. Sponsor: Cartesian Therapeutics, Inc. (RNAC). We track 3 catalyst events for this program: 3 upcoming and 0 in the record. A PDUFA date is the FDA's target date to complete review of a marketing application; a readout is the sponsor's expected date for clinical trial results. What a PDUFA date is · why we do not compare trial results across drugs.
The next tracked catalyst for Descartes-08 (mRNA CAR-T) is a Readout in Q1 2027.
No FDA decision for Descartes-08 (mRNA CAR-T) is in our archive yet.
In our records Descartes-08 (mRNA CAR-T) is under review or in development for Myasthenia gravis; Myositis.
Cartesian Therapeutics, Inc. (RNAC).
FDA announcements, sponsor press releases and SEC filings. Each FDA decision links its own page, which names its source or says plainly that it has none.